| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Balazs Halmos | |
| Zhenfeng Zhang | |||
| Xiaoliang Wu | |||
| Xuewen Liu | |||
| Chang Youl Lee | |||
| Sanjay Koul | |||
| P2860 | cites work | Structural basis for Gas6-Axl signalling. | Q24299209 |
| TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway | Q24307937 | ||
| Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site | Q24309038 | ||
| TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition | Q24310051 | ||
| axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase | Q24310364 | ||
| The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade | Q24310383 | ||
| Reevaluation of the roles of protein S and gas6 as ligands for the receptor tyrosine kinase Rse/Tyro 3 | Q24321841 | ||
| Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival | Q24546291 | ||
| MET inhibitors in combination with other therapies in non-small cell lung cancer | Q26823203 | ||
| Epithelial-mesenchymal transitions: insights from development | Q26865944 | ||
| Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily | Q27654013 | ||
| LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models | Q27675641 | ||
| The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. | Q39381139 | ||
| Profiling of antibody production against xenograft-released proteins by protein microarrays discovers prostate cancer markers | Q39434080 | ||
| Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth | Q39472261 | ||
| Silencing of Rac1 modifies lung cancer cell migration, invasion and actin cytoskeleton rearrangements and enhances chemosensitivity to antitumor drugs | Q39491304 | ||
| Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. | Q39499581 | ||
| Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells | Q39512409 | ||
| Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer | Q39587794 | ||
| Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer | Q39592978 | ||
| AXL regulates mesothelioma proliferation and invasiveness | Q39623714 | ||
| Axl promotes cutaneous squamous cell carcinoma survival through negative regulation of pro-apoptotic Bcl-2 family members. | Q39633320 | ||
| Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer | Q39634782 | ||
| Differential expression of Axl in hepatocellular carcinoma and correlation with tumor lymphatic metastasis | Q39679535 | ||
| An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies | Q39684120 | ||
| Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer | Q39741566 | ||
| Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. | Q39813764 | ||
| Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis | Q39820482 | ||
| The human receptor tyrosine kinase Axl gene--promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation | Q39975842 | ||
| A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells | Q39991840 | ||
| AXL is a potential target for therapeutic intervention in breast cancer progression. | Q40002526 | ||
| Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway | Q40190955 | ||
| A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. | Q40289611 | ||
| Multiple roles for the receptor tyrosine kinase axl in tumor formation | Q40360957 | ||
| Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer | Q40390404 | ||
| An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system | Q41183910 | ||
| Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines | Q41235107 | ||
| Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation | Q42155234 | ||
| Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast | Q43695197 | ||
| Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion | Q43777232 | ||
| Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells | Q43805305 | ||
| Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation | Q44192096 | ||
| Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma | Q44378605 | ||
| Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival | Q44732841 | ||
| Coexpression of Gas6/Axl in human ovarian cancers | Q45081570 | ||
| Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. | Q45945576 | ||
| Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia | Q46576090 | ||
| Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme | Q46825520 | ||
| Cloning and developmental expression analysis of the murine c-mer tyrosine kinase | Q48072816 | ||
| The murine ufo receptor: molecular cloning, chromosomal localization and in situ expression analysis | Q48168458 | ||
| TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. | Q53090999 | ||
| TAM receptor function in the retinal pigment epithelium | Q56878898 | ||
| First Axl inhibitor enters clinical trials | Q85717127 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. | Q27852553 | ||
| C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration | Q28244101 | ||
| Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl | Q28277798 | ||
| The Dtk receptor tyrosine kinase, which binds protein S, is expressed during hematopoiesis | Q28280019 | ||
| Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis | Q28286679 | ||
| Genes specifically expressed at growth arrest of mammalian cells | Q28297811 | ||
| Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases | Q28298018 | ||
| Twist mediates suppression of inflammation by type I IFNs and Axl | Q28509359 | ||
| Axl, a receptor tyrosine kinase, mediates flow-induced vascular remodeling | Q28513114 | ||
| Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis | Q28513697 | ||
| Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family | Q28585446 | ||
| Tyro-3 family receptors are essential regulators of mammalian spermatogenesis | Q28585555 | ||
| Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer | Q28588141 | ||
| XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. | Q30428632 | ||
| Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. | Q31929744 | ||
| The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. | Q33357894 | ||
| Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma | Q33514834 | ||
| GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. | Q33622570 | ||
| Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival | Q33667156 | ||
| Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. | Q33724277 | ||
| Immunobiology of the TAM receptors | Q33796991 | ||
| A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b | Q33918209 | ||
| Galectin-3 is a new MerTK-specific eat-me signal | Q33972695 | ||
| TAM receptor tyrosine kinases: expression, disease and oncogenesis in the central nervous system | Q34077622 | ||
| RETRACTED: Soluble Axl is generated by ADAM10-dependent cleavage and associates with Gas6 in mouse serum | Q34097404 | ||
| Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. | Q34307548 | ||
| The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma | Q34515144 | ||
| PTEN: The down side of PI 3-kinase signalling. | Q34540849 | ||
| TAZ expression as a prognostic indicator in colorectal cancer | Q34571020 | ||
| Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. | Q34576544 | ||
| The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy | Q34667753 | ||
| Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands. | Q37955105 | ||
| A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors | Q38304282 | ||
| Coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases Axl and Sky in human uterine endometrial cancers | Q38353801 | ||
| MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme | Q39012846 | ||
| Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma | Q39063025 | ||
| MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation | Q39069521 | ||
| Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanism | Q39092295 | ||
| Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation | Q39102364 | ||
| Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET. | Q39103018 | ||
| S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab | Q39134353 | ||
| Secretome proteins as candidate biomarkers for aggressive thyroid carcinomas. | Q39210485 | ||
| YES-associated protein 1 promotes adenocarcinoma growth and metastasis through activation of the receptor tyrosine kinase Axl. | Q39214406 | ||
| ABL regulation by AXL promotes cisplatin resistance in esophageal cancer | Q39250660 | ||
| HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors | Q39263953 | ||
| The role of Rac1 in the regulation of NF-κB activity, cell proliferation, and cell migration in non-small cell lung carcinoma | Q39355557 | ||
| Expression of axl in lung adenocarcinoma and correlation with tumor progression | Q34768498 | ||
| Phosphoproteomic analysis of Her2/neu signaling and inhibition | Q34772747 | ||
| TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer | Q34794927 | ||
| Macrophage regulation by Tyro 3 family receptors | Q35031954 | ||
| Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer. | Q35076221 | ||
| Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation | Q35390011 | ||
| Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma | Q35486521 | ||
| Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells | Q35677075 | ||
| Personalizing therapy with targeted agents in non-small cell lung cancer | Q35679361 | ||
| Transforming activity of retroviral genomes encoding Gag-Axl fusion proteins | Q35872635 | ||
| AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. | Q35899490 | ||
| Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer | Q36044487 | ||
| Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA | Q36054278 | ||
| Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition | Q36110345 | ||
| AXL is an essential factor and therapeutic target for metastatic ovarian cancer | Q36127308 | ||
| Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer | Q36128435 | ||
| Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer | Q36413157 | ||
| Targeting Axl with an high-affinity inhibitory aptamer. | Q36460465 | ||
| Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl | Q36481940 | ||
| Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases | Q36493822 | ||
| An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance | Q36597042 | ||
| The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma | Q36671963 | ||
| Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target | Q36682854 | ||
| Axl-dependent signalling: a clinical update | Q36720080 | ||
| Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer | Q36822111 | ||
| The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target | Q37182283 | ||
| Biology of the TAM receptors | Q37258717 | ||
| Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients | Q37369038 | ||
| AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. | Q37451822 | ||
| Imaging Axl expression in pancreatic and prostate cancer xenografts | Q37571724 | ||
| Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype | Q37589120 | ||
| The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells | Q37627397 | ||
| AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells | Q37715171 | ||
| Targeting Axl and Mer kinases in cancer | Q37936028 | ||
| P275 | copyright license | Creative Commons Attribution 2.5 Generic | Q18810333 |
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | receptor tyrosine kinase | Q420511 |
| neoplasm | Q1216998 | ||
| proto-oncogene protein | Q66020913 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 9546-63 | |
| P577 | publication date | 2014-10-30 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | AXL kinase as a novel target for cancer therapy | |
| P478 | volume | 5 |
| Q96641372 | A single-cell landscape of high-grade serous ovarian cancer |
| Q37189265 | ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling |
| Q92814606 | AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells |
| Q35843071 | AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas |
| Q36414168 | AXL is an oncotarget in human colorectal cancer. |
| Q37684598 | AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer |
| Q42359111 | AXL-GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases |
| Q91906063 | Animal models of well-differentiated/dedifferentiated liposarcoma: utility and limitations |
| Q40420136 | Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer |
| Q92062648 | Axl and autophagy LC3 expression in tumors is strongly associated with clinical prognosis of hepatocellular carcinoma patients after curative resection |
| Q49737040 | Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models |
| Q58804596 | Axl inhibitor R428 induces apoptosis of cancer cells by blocking lysosomal acidification and recycling independent of Axl inhibition |
| Q64097927 | Axl signaling is an important mediator of tumor angiogenesis |
| Q39095878 | Biomarkers for EMT and MET in breast cancer: An update |
| Q47233500 | Cell softening in malignant progression of human lung cancer cells by activation of receptor tyrosine kinase AXL. |
| Q48521717 | Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy. |
| Q92323801 | Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors |
| Q44312660 | Combined Inhibitions of Glycolysis and AKT/autophagy Can Overcome Resistance to EGFR-targeted Therapy of Lung Cancer |
| Q26740594 | Contemporary Treatment of Metastatic Renal Cell Carcinoma |
| Q90147731 | Curcumin-Synthetic Analogs Library Screening by Docking and Quantitative Structure-Activity Relationship Studies for AXL Tyrosine Kinase Inhibition in Cancers |
| Q93187791 | DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model |
| Q41612823 | Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy |
| Q93059778 | Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system |
| Q37094024 | Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq |
| Q54123522 | Engineering Axl specific CAR and SynNotch receptor for cancer therapy. |
| Q39414887 | Epithelial-to-Pericyte Transition in Cancer. |
| Q38728165 | Fisetin, a dietary phytochemical, overcomes Erlotinib-resistance of lung adenocarcinoma cells through inhibition of MAPK and AKT pathways |
| Q49636410 | Function of Axl receptor tyrosine kinase in non-small cell lung cancer |
| Q30845910 | G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance |
| Q36808017 | Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents |
| Q38763966 | Gene of the month: Axl. |
| Q36557240 | Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways |
| Q39025087 | Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis |
| Q37545045 | Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies |
| Q40007526 | Integrative radiogenomic analysis for multicentric radiophenotype in glioblastoma |
| Q38850971 | Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia |
| Q41082549 | LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinoma |
| Q41344145 | Marsdenia tenacissima extract overcomes Axl- and Met-mediated erlotinib and gefitinib cross-resistance in non-small cell lung cancer cells |
| Q30840180 | Mechanosensing Controlled Directly by Tyrosine Kinases. |
| Q26769611 | Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies? |
| Q43246838 | MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer |
| Q38746437 | Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase |
| Q50027090 | NEO212 Inhibits Migration and Invasion of Glioma Stem Cells. |
| Q36461930 | Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells |
| Q38972265 | New twists in the AXL(e) of tumor progression |
| Q35558057 | Novel and emerging targeted-based cancer therapy agents and methods |
| Q61809725 | Oxidized Vitamin C (DHA) Overcomes Resistance to EGFR-targeted Therapy of Lung Cancer through Disturbing Energy Homeostasis |
| Q37227987 | Peroxisome proliferator-activated receptor-γ agonist troglitazone suppresses transforming growth factor-β1 signalling through miR-92b upregulation-inhibited Axl expression in human keloid fibroblasts in vitro |
| Q99238235 | Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics |
| Q41847773 | Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL. |
| Q47261659 | Protein biomarkers for subtyping breast cancer and implications for future research. |
| Q37699039 | Regulated intramembrane proteolysis of the AXL receptor kinase generates an intracellular domain that localizes in the nucleus of cancer cells |
| Q33719952 | Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations |
| Q89879065 | Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia |
| Q91642878 | SMAD signaling promotes melanoma metastasis independently of phenotype switching |
| Q90370791 | Stromal Gas6 promotes the progression of premalignant mammary cells |
| Q37696310 | Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling |
| Q92025094 | Targeting AXL and RAGE to prevent geminin overexpression-induced triple-negative breast cancer metastasis |
| Q41093141 | Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer |
| Q52657032 | Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. |
| Q47701436 | Targeting Gas6/TAM in cancer cells and tumor microenvironment |
| Q36527950 | Targeting protein kinases to reverse multidrug resistance in sarcoma. |
| Q46659031 | The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase |
| Q51146366 | The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. |
| Q27928010 | The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy |
| Q26749110 | The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer |
| Q90424175 | The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis |
| Q64900257 | Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. |
| Q92659769 | Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer |
| Q90473266 | Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target |
| Q55070013 | When good transforming growth factor-β turns bad in hepatocellular carcinoma: Axl takes the stage. |
| Q66679244 | Zika Virus Transmission Through Blood Tissue Barriers |
| Q39456830 | mTOR Signaling Confers Resistance to Targeted Cancer Drugs. |
Search more.